nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—systemic lupus erythematosus—systemic scleroderma	0.389	0.514	CtDrD
Leflunomide—rheumatoid arthritis—systemic scleroderma	0.367	0.486	CtDrD
Leflunomide—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0387	0.476	CbGbCtD
Leflunomide—CYP1A2—Pentoxifylline—systemic scleroderma	0.0271	0.333	CbGbCtD
Leflunomide—ABCG2—Methotrexate—systemic scleroderma	0.0155	0.191	CbGbCtD
Leflunomide—CYP2C9—cardial valve—systemic scleroderma	0.00801	0.314	CbGeAlD
Leflunomide—DHODH—skin of body—systemic scleroderma	0.00235	0.0921	CbGeAlD
Leflunomide—DHODH—tendon—systemic scleroderma	0.00179	0.0701	CbGeAlD
Leflunomide—PTK2B—connective tissue—systemic scleroderma	0.00165	0.0646	CbGeAlD
Leflunomide—DHODH—lung—systemic scleroderma	0.00157	0.0616	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—systemic scleroderma	0.00151	0.0591	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—systemic scleroderma	0.00124	0.0486	CbGeAlD
Leflunomide—PTK2B—digestive system—systemic scleroderma	0.00119	0.0467	CbGeAlD
Leflunomide—PTK2B—tendon—systemic scleroderma	0.00113	0.0444	CbGeAlD
Leflunomide—PTK2B—lung—systemic scleroderma	0.000994	0.039	CbGeAlD
Leflunomide—AHR—digestive system—systemic scleroderma	0.000979	0.0384	CbGeAlD
Leflunomide—AHR—tendon—systemic scleroderma	0.000931	0.0365	CbGeAlD
Leflunomide—AHR—lung—systemic scleroderma	0.000817	0.0321	CbGeAlD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—SMAD7—systemic scleroderma	0.000529	0.065	CbGpPWpGaD
Leflunomide—PTK2B—Alpha-synuclein signaling—BLK—systemic scleroderma	0.000498	0.0612	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000417	0.0513	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TOP1—systemic scleroderma	0.000373	0.0457	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—CSF1—systemic scleroderma	0.000369	0.0453	CbGpPWpGaD
Leflunomide—CYP1A2—digestive system—systemic scleroderma	0.000365	0.0143	CbGeAlD
Leflunomide—CYP2C9—digestive system—systemic scleroderma	0.000347	0.0136	CbGeAlD
Leflunomide—PTK2B—Integrins in angiogenesis—COL1A2—systemic scleroderma	0.000336	0.0413	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—COL1A2—systemic scleroderma	0.000336	0.0413	CbGpPWpGaD
Leflunomide—ABCG2—lung—systemic scleroderma	0.000317	0.0124	CbGeAlD
Leflunomide—CYP1A2—lung—systemic scleroderma	0.000305	0.012	CbGeAlD
Leflunomide—PTK2B—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.000283	0.0348	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.000258	0.0317	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000243	0.0298	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD247—systemic scleroderma	0.00023	0.0282	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000224	0.0276	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000221	0.0272	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP2—systemic scleroderma	0.000209	0.0256	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—EDN1—systemic scleroderma	0.000182	0.0224	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000172	0.0211	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP9—systemic scleroderma	0.000157	0.0193	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—MMP1—systemic scleroderma	0.000153	0.0188	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000153	0.0187	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000149	0.0183	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000139	0.017	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000136	0.0167	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000121	0.0149	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL1A—systemic scleroderma	0.000118	0.0144	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP2—systemic scleroderma	0.000117	0.0144	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000104	0.0128	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—systemic scleroderma	0.000101	0.0124	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	9.69e-05	0.0119	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	9.26e-05	0.0114	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—systemic scleroderma	8.79e-05	0.0108	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	8.16e-05	0.01	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Lisinopril—systemic scleroderma	7.65e-05	0.000592	CcSEcCtD
Leflunomide—Dyspepsia—Mycophenolic acid—systemic scleroderma	7.63e-05	0.000591	CcSEcCtD
Leflunomide—Neutropenia—Prednisone—systemic scleroderma	7.63e-05	0.000591	CcSEcCtD
Leflunomide—Tachycardia—Lisinopril—systemic scleroderma	7.62e-05	0.00059	CcSEcCtD
Leflunomide—Body temperature increased—Azathioprine—systemic scleroderma	7.61e-05	0.000589	CcSEcCtD
Leflunomide—Abdominal pain—Azathioprine—systemic scleroderma	7.61e-05	0.000589	CcSEcCtD
Leflunomide—Skin disorder—Lisinopril—systemic scleroderma	7.59e-05	0.000588	CcSEcCtD
Leflunomide—Malaise—Mycophenolate mofetil—systemic scleroderma	7.56e-05	0.000586	CcSEcCtD
Leflunomide—Hyperhidrosis—Lisinopril—systemic scleroderma	7.55e-05	0.000585	CcSEcCtD
Leflunomide—Diarrhoea—Captopril—systemic scleroderma	7.55e-05	0.000584	CcSEcCtD
Leflunomide—Decreased appetite—Mycophenolic acid—systemic scleroderma	7.54e-05	0.000584	CcSEcCtD
Leflunomide—Vertigo—Mycophenolate mofetil—systemic scleroderma	7.53e-05	0.000583	CcSEcCtD
Leflunomide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	7.51e-05	0.000581	CcSEcCtD
Leflunomide—AHR—Adipogenesis—TGFB1—systemic scleroderma	7.49e-05	0.00919	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	7.49e-05	0.00058	CcSEcCtD
Leflunomide—Fatigue—Mycophenolic acid—systemic scleroderma	7.48e-05	0.000579	CcSEcCtD
Leflunomide—Nausea—Mometasone—systemic scleroderma	7.46e-05	0.000578	CcSEcCtD
Leflunomide—Anorexia—Lisinopril—systemic scleroderma	7.45e-05	0.000577	CcSEcCtD
Leflunomide—Constipation—Mycophenolic acid—systemic scleroderma	7.42e-05	0.000574	CcSEcCtD
Leflunomide—Pain—Mycophenolic acid—systemic scleroderma	7.42e-05	0.000574	CcSEcCtD
Leflunomide—Palpitations—Mycophenolate mofetil—systemic scleroderma	7.41e-05	0.000574	CcSEcCtD
Leflunomide—DHODH—Metabolism—HSPG2—systemic scleroderma	7.4e-05	0.00909	CbGpPWpGaD
Leflunomide—Weight decreased—Prednisone—systemic scleroderma	7.38e-05	0.000572	CcSEcCtD
Leflunomide—Hyperglycaemia—Prednisone—systemic scleroderma	7.36e-05	0.00057	CcSEcCtD
Leflunomide—Cough—Mycophenolate mofetil—systemic scleroderma	7.32e-05	0.000567	CcSEcCtD
Leflunomide—Hypotension—Lisinopril—systemic scleroderma	7.3e-05	0.000565	CcSEcCtD
Leflunomide—Dizziness—Captopril—systemic scleroderma	7.29e-05	0.000565	CcSEcCtD
Leflunomide—Liver function test abnormal—Methotrexate—systemic scleroderma	7.28e-05	0.000564	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	7.26e-05	0.00892	CbGpPWpGaD
Leflunomide—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.000561	CcSEcCtD
Leflunomide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.15e-05	0.000553	CcSEcCtD
Leflunomide—Myalgia—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.000553	CcSEcCtD
Leflunomide—Chest pain—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.000553	CcSEcCtD
Leflunomide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.000553	CcSEcCtD
Leflunomide—Neuropathy peripheral—Prednisone—systemic scleroderma	7.13e-05	0.000552	CcSEcCtD
Leflunomide—Breast disorder—Methotrexate—systemic scleroderma	7.13e-05	0.000552	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	7.12e-05	0.000551	CcSEcCtD
Leflunomide—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.11e-05	0.000551	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	7.1e-05	0.00055	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1B—systemic scleroderma	7.1e-05	0.00872	CbGpPWpGaD
Leflunomide—Hypersensitivity—Azathioprine—systemic scleroderma	7.09e-05	0.000549	CcSEcCtD
Leflunomide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.09e-05	0.000549	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	7.09e-05	0.000549	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—systemic scleroderma	7.07e-05	0.00868	CbGpPWpGaD
Leflunomide—Insomnia—Lisinopril—systemic scleroderma	7.06e-05	0.000547	CcSEcCtD
Leflunomide—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.05e-05	0.000546	CcSEcCtD
Leflunomide—Paraesthesia—Lisinopril—systemic scleroderma	7.01e-05	0.000543	CcSEcCtD
Leflunomide—Vomiting—Captopril—systemic scleroderma	7.01e-05	0.000543	CcSEcCtD
Leflunomide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	6.98e-05	0.000541	CcSEcCtD
Leflunomide—Dyspnoea—Lisinopril—systemic scleroderma	6.96e-05	0.000539	CcSEcCtD
Leflunomide—Rash—Captopril—systemic scleroderma	6.95e-05	0.000539	CcSEcCtD
Leflunomide—Dermatitis—Captopril—systemic scleroderma	6.95e-05	0.000538	CcSEcCtD
Leflunomide—Headache—Captopril—systemic scleroderma	6.91e-05	0.000535	CcSEcCtD
Leflunomide—Dyspepsia—Lisinopril—systemic scleroderma	6.88e-05	0.000532	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—NOS3—systemic scleroderma	6.86e-05	0.00842	CbGpPWpGaD
Leflunomide—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.86e-05	0.000531	CcSEcCtD
Leflunomide—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.86e-05	0.000531	CcSEcCtD
Leflunomide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	6.84e-05	0.00053	CcSEcCtD
Leflunomide—Asthma—Methotrexate—systemic scleroderma	6.82e-05	0.000528	CcSEcCtD
Leflunomide—Infection—Mycophenolate mofetil—systemic scleroderma	6.8e-05	0.000527	CcSEcCtD
Leflunomide—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	6.8e-05	0.00835	CbGpPWpGaD
Leflunomide—Decreased appetite—Lisinopril—systemic scleroderma	6.79e-05	0.000526	CcSEcCtD
Leflunomide—Eosinophilia—Methotrexate—systemic scleroderma	6.75e-05	0.000523	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	6.74e-05	0.000522	CcSEcCtD
Leflunomide—Fatigue—Lisinopril—systemic scleroderma	6.73e-05	0.000522	CcSEcCtD
Leflunomide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	6.71e-05	0.00052	CcSEcCtD
Leflunomide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.7e-05	0.000519	CcSEcCtD
Leflunomide—Pancreatitis—Methotrexate—systemic scleroderma	6.68e-05	0.000518	CcSEcCtD
Leflunomide—Pain—Lisinopril—systemic scleroderma	6.68e-05	0.000517	CcSEcCtD
Leflunomide—Constipation—Lisinopril—systemic scleroderma	6.68e-05	0.000517	CcSEcCtD
Leflunomide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.68e-05	0.000517	CcSEcCtD
Leflunomide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	6.65e-05	0.000515	CcSEcCtD
Leflunomide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.62e-05	0.000512	CcSEcCtD
Leflunomide—Diarrhoea—Azathioprine—systemic scleroderma	6.59e-05	0.00051	CcSEcCtD
Leflunomide—Haemoglobin—Prednisone—systemic scleroderma	6.56e-05	0.000508	CcSEcCtD
Leflunomide—Nausea—Captopril—systemic scleroderma	6.55e-05	0.000507	CcSEcCtD
Leflunomide—Haemorrhage—Prednisone—systemic scleroderma	6.53e-05	0.000506	CcSEcCtD
Leflunomide—Anorexia—Mycophenolate mofetil—systemic scleroderma	6.52e-05	0.000505	CcSEcCtD
Leflunomide—Pancytopenia—Methotrexate—systemic scleroderma	6.47e-05	0.000501	CcSEcCtD
Leflunomide—Feeling abnormal—Lisinopril—systemic scleroderma	6.44e-05	0.000498	CcSEcCtD
Leflunomide—Connective tissue disorder—Prednisone—systemic scleroderma	6.42e-05	0.000497	CcSEcCtD
Leflunomide—Hypotension—Mycophenolate mofetil—systemic scleroderma	6.39e-05	0.000495	CcSEcCtD
Leflunomide—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.39e-05	0.000495	CcSEcCtD
Leflunomide—Neutropenia—Methotrexate—systemic scleroderma	6.37e-05	0.000494	CcSEcCtD
Leflunomide—Dysuria—Methotrexate—systemic scleroderma	6.37e-05	0.000494	CcSEcCtD
Leflunomide—Dizziness—Azathioprine—systemic scleroderma	6.37e-05	0.000493	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	6.34e-05	0.000491	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	6.23e-05	0.000483	CcSEcCtD
Leflunomide—Asthenia—Mycophenolic acid—systemic scleroderma	6.22e-05	0.000482	CcSEcCtD
Leflunomide—Urticaria—Lisinopril—systemic scleroderma	6.2e-05	0.000481	CcSEcCtD
Leflunomide—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000479	CcSEcCtD
Leflunomide—Abdominal pain—Lisinopril—systemic scleroderma	6.17e-05	0.000478	CcSEcCtD
Leflunomide—Body temperature increased—Lisinopril—systemic scleroderma	6.17e-05	0.000478	CcSEcCtD
Leflunomide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.15e-05	0.000476	CcSEcCtD
Leflunomide—Pruritus—Mycophenolic acid—systemic scleroderma	6.14e-05	0.000475	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL1B—systemic scleroderma	6.13e-05	0.00753	CbGpPWpGaD
Leflunomide—Vomiting—Azathioprine—systemic scleroderma	6.12e-05	0.000474	CcSEcCtD
Leflunomide—Pneumonia—Methotrexate—systemic scleroderma	6.11e-05	0.000473	CcSEcCtD
Leflunomide—Eye disorder—Prednisone—systemic scleroderma	6.1e-05	0.000473	CcSEcCtD
Leflunomide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.1e-05	0.000473	CcSEcCtD
Leflunomide—Infestation—Methotrexate—systemic scleroderma	6.08e-05	0.000471	CcSEcCtD
Leflunomide—Infestation NOS—Methotrexate—systemic scleroderma	6.08e-05	0.000471	CcSEcCtD
Leflunomide—Rash—Azathioprine—systemic scleroderma	6.07e-05	0.00047	CcSEcCtD
Leflunomide—Dermatitis—Azathioprine—systemic scleroderma	6.06e-05	0.00047	CcSEcCtD
Leflunomide—Headache—Azathioprine—systemic scleroderma	6.03e-05	0.000467	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	6.03e-05	0.000467	CcSEcCtD
Leflunomide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.02e-05	0.000467	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—systemic scleroderma	5.98e-05	0.000463	CcSEcCtD
Leflunomide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.95e-05	0.000461	CcSEcCtD
Leflunomide—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.93e-05	0.000459	CcSEcCtD
Leflunomide—Stomatitis—Methotrexate—systemic scleroderma	5.93e-05	0.000459	CcSEcCtD
Leflunomide—Conjunctivitis—Methotrexate—systemic scleroderma	5.91e-05	0.000458	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.91e-05	0.000458	CcSEcCtD
Leflunomide—Immune system disorder—Prednisone—systemic scleroderma	5.9e-05	0.000457	CcSEcCtD
Leflunomide—Constipation—Mycophenolate mofetil—systemic scleroderma	5.85e-05	0.000453	CcSEcCtD
Leflunomide—Pain—Mycophenolate mofetil—systemic scleroderma	5.85e-05	0.000453	CcSEcCtD
Leflunomide—Arrhythmia—Prednisone—systemic scleroderma	5.83e-05	0.000452	CcSEcCtD
Leflunomide—Haematuria—Methotrexate—systemic scleroderma	5.8e-05	0.000449	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	5.78e-05	0.0071	CbGpPWpGaD
Leflunomide—Alopecia—Prednisone—systemic scleroderma	5.77e-05	0.000447	CcSEcCtD
Leflunomide—Hypersensitivity—Lisinopril—systemic scleroderma	5.75e-05	0.000446	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—systemic scleroderma	5.75e-05	0.000445	CcSEcCtD
Leflunomide—Dizziness—Mycophenolic acid—systemic scleroderma	5.73e-05	0.000444	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—systemic scleroderma	5.73e-05	0.000444	CcSEcCtD
Leflunomide—Mental disorder—Prednisone—systemic scleroderma	5.72e-05	0.000443	CcSEcCtD
Leflunomide—Nausea—Azathioprine—systemic scleroderma	5.72e-05	0.000443	CcSEcCtD
Leflunomide—Malnutrition—Prednisone—systemic scleroderma	5.68e-05	0.00044	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—systemic scleroderma	5.67e-05	0.000439	CcSEcCtD
Leflunomide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.64e-05	0.000437	CcSEcCtD
Leflunomide—DHODH—Metabolism—CTGF—systemic scleroderma	5.61e-05	0.00689	CbGpPWpGaD
Leflunomide—Asthenia—Lisinopril—systemic scleroderma	5.6e-05	0.000434	CcSEcCtD
Leflunomide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.6e-05	0.000433	CcSEcCtD
Leflunomide—Pruritus—Lisinopril—systemic scleroderma	5.53e-05	0.000428	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—systemic scleroderma	5.52e-05	0.00677	CbGpPWpGaD
Leflunomide—Vomiting—Mycophenolic acid—systemic scleroderma	5.51e-05	0.000427	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	5.49e-05	0.00674	CbGpPWpGaD
Leflunomide—Haemoglobin—Methotrexate—systemic scleroderma	5.48e-05	0.000425	CcSEcCtD
Leflunomide—Rash—Mycophenolic acid—systemic scleroderma	5.47e-05	0.000423	CcSEcCtD
Leflunomide—Dermatitis—Mycophenolic acid—systemic scleroderma	5.46e-05	0.000423	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—systemic scleroderma	5.46e-05	0.000423	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—systemic scleroderma	5.46e-05	0.000423	CcSEcCtD
Leflunomide—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000421	CcSEcCtD
Leflunomide—Headache—Mycophenolic acid—systemic scleroderma	5.43e-05	0.000421	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—systemic scleroderma	5.42e-05	0.000419	CcSEcCtD
Leflunomide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.41e-05	0.000419	CcSEcCtD
Leflunomide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.41e-05	0.000419	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—systemic scleroderma	5.39e-05	0.000417	CcSEcCtD
Leflunomide—Vision blurred—Prednisone—systemic scleroderma	5.36e-05	0.000415	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—systemic scleroderma	5.35e-05	0.000414	CcSEcCtD
Leflunomide—Diarrhoea—Lisinopril—systemic scleroderma	5.34e-05	0.000414	CcSEcCtD
Leflunomide—Ill-defined disorder—Prednisone—systemic scleroderma	5.27e-05	0.000408	CcSEcCtD
Leflunomide—Anaemia—Prednisone—systemic scleroderma	5.25e-05	0.000407	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	5.21e-05	0.0064	CbGpPWpGaD
Leflunomide—Angioedema—Prednisone—systemic scleroderma	5.19e-05	0.000402	CcSEcCtD
Leflunomide—Dizziness—Lisinopril—systemic scleroderma	5.16e-05	0.0004	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—systemic scleroderma	5.16e-05	0.0004	CcSEcCtD
Leflunomide—Nausea—Mycophenolic acid—systemic scleroderma	5.15e-05	0.000399	CcSEcCtD
Leflunomide—Malaise—Prednisone—systemic scleroderma	5.13e-05	0.000397	CcSEcCtD
Leflunomide—Vertigo—Prednisone—systemic scleroderma	5.11e-05	0.000395	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—systemic scleroderma	5.1e-05	0.000395	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—systemic scleroderma	5.06e-05	0.000392	CcSEcCtD
Leflunomide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.00039	CcSEcCtD
Leflunomide—Vomiting—Lisinopril—systemic scleroderma	4.97e-05	0.000385	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—systemic scleroderma	4.93e-05	0.000382	CcSEcCtD
Leflunomide—Rash—Lisinopril—systemic scleroderma	4.92e-05	0.000381	CcSEcCtD
Leflunomide—Dermatitis—Lisinopril—systemic scleroderma	4.92e-05	0.000381	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—systemic scleroderma	4.92e-05	0.000381	CcSEcCtD
Leflunomide—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.91e-05	0.00038	CcSEcCtD
Leflunomide—Hypertension—Prednisone—systemic scleroderma	4.91e-05	0.00038	CcSEcCtD
Leflunomide—Chills—Methotrexate—systemic scleroderma	4.9e-05	0.000379	CcSEcCtD
Leflunomide—Headache—Lisinopril—systemic scleroderma	4.89e-05	0.000379	CcSEcCtD
Leflunomide—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.84e-05	0.000375	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—systemic scleroderma	4.84e-05	0.000375	CcSEcCtD
Leflunomide—Myalgia—Prednisone—systemic scleroderma	4.84e-05	0.000375	CcSEcCtD
Leflunomide—Anxiety—Prednisone—systemic scleroderma	4.82e-05	0.000373	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—systemic scleroderma	4.82e-05	0.000373	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	4.81e-05	0.000372	CcSEcCtD
Leflunomide—Discomfort—Prednisone—systemic scleroderma	4.78e-05	0.00037	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—systemic scleroderma	4.78e-05	0.00037	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—systemic scleroderma	4.75e-05	0.000368	CcSEcCtD
Leflunomide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.000363	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—systemic scleroderma	4.65e-05	0.00036	CcSEcCtD
Leflunomide—Nausea—Lisinopril—systemic scleroderma	4.64e-05	0.000359	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—systemic scleroderma	4.64e-05	0.000359	CcSEcCtD
Leflunomide—Infection—Prednisone—systemic scleroderma	4.61e-05	0.000357	CcSEcCtD
Leflunomide—Back pain—Methotrexate—systemic scleroderma	4.59e-05	0.000356	CcSEcCtD
Leflunomide—Nervous system disorder—Prednisone—systemic scleroderma	4.55e-05	0.000352	CcSEcCtD
Leflunomide—Tachycardia—Prednisone—systemic scleroderma	4.53e-05	0.000351	CcSEcCtD
Leflunomide—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.53e-05	0.00035	CcSEcCtD
Leflunomide—Skin disorder—Prednisone—systemic scleroderma	4.51e-05	0.000349	CcSEcCtD
Leflunomide—Hyperhidrosis—Prednisone—systemic scleroderma	4.48e-05	0.000347	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—systemic scleroderma	4.48e-05	0.000347	CcSEcCtD
Leflunomide—Anorexia—Prednisone—systemic scleroderma	4.42e-05	0.000342	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—systemic scleroderma	4.41e-05	0.000341	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—systemic scleroderma	4.39e-05	0.00034	CcSEcCtD
Leflunomide—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.35e-05	0.000337	CcSEcCtD
Leflunomide—Rash—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000334	CcSEcCtD
Leflunomide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000334	CcSEcCtD
Leflunomide—Headache—Mycophenolate mofetil—systemic scleroderma	4.29e-05	0.000332	CcSEcCtD
Leflunomide—Malaise—Methotrexate—systemic scleroderma	4.28e-05	0.000332	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—systemic scleroderma	4.27e-05	0.000331	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—systemic scleroderma	4.25e-05	0.000329	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.23e-05	0.000327	CcSEcCtD
Leflunomide—Insomnia—Prednisone—systemic scleroderma	4.2e-05	0.000325	CcSEcCtD
Leflunomide—Paraesthesia—Prednisone—systemic scleroderma	4.17e-05	0.000323	CcSEcCtD
Leflunomide—Cough—Methotrexate—systemic scleroderma	4.15e-05	0.000321	CcSEcCtD
Leflunomide—Dyspepsia—Prednisone—systemic scleroderma	4.08e-05	0.000316	CcSEcCtD
Leflunomide—Nausea—Mycophenolate mofetil—systemic scleroderma	4.06e-05	0.000315	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—systemic scleroderma	4.04e-05	0.000313	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—systemic scleroderma	4.04e-05	0.000313	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—systemic scleroderma	4.04e-05	0.000313	CcSEcCtD
Leflunomide—Decreased appetite—Prednisone—systemic scleroderma	4.03e-05	0.000312	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.02e-05	0.000311	CcSEcCtD
Leflunomide—Fatigue—Prednisone—systemic scleroderma	4e-05	0.00031	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—systemic scleroderma	4e-05	0.000309	CcSEcCtD
Leflunomide—Constipation—Prednisone—systemic scleroderma	3.97e-05	0.000307	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—systemic scleroderma	3.88e-05	0.0003	CcSEcCtD
Leflunomide—Infection—Methotrexate—systemic scleroderma	3.85e-05	0.000298	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisone—systemic scleroderma	3.82e-05	0.000296	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—systemic scleroderma	3.8e-05	0.000294	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—systemic scleroderma	3.8e-05	0.000294	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—systemic scleroderma	3.79e-05	0.000294	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—systemic scleroderma	3.77e-05	0.000292	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—systemic scleroderma	3.75e-05	0.00029	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—systemic scleroderma	3.7e-05	0.000286	CcSEcCtD
Leflunomide—Urticaria—Prednisone—systemic scleroderma	3.69e-05	0.000285	CcSEcCtD
Leflunomide—Body temperature increased—Prednisone—systemic scleroderma	3.67e-05	0.000284	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—systemic scleroderma	3.67e-05	0.000284	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—systemic scleroderma	3.62e-05	0.000281	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.53e-05	0.000274	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—systemic scleroderma	3.51e-05	0.000272	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—systemic scleroderma	3.48e-05	0.00027	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—systemic scleroderma	3.46e-05	0.000268	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisone—systemic scleroderma	3.42e-05	0.000265	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—systemic scleroderma	3.41e-05	0.000264	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—systemic scleroderma	3.37e-05	0.000261	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.35e-05	0.000259	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—systemic scleroderma	3.34e-05	0.000259	CcSEcCtD
Leflunomide—Asthenia—Prednisone—systemic scleroderma	3.33e-05	0.000258	CcSEcCtD
Leflunomide—Pain—Methotrexate—systemic scleroderma	3.32e-05	0.000257	CcSEcCtD
Leflunomide—Pruritus—Prednisone—systemic scleroderma	3.28e-05	0.000254	CcSEcCtD
Leflunomide—PTK2B—Immune System—CSK—systemic scleroderma	3.22e-05	0.00395	CbGpPWpGaD
Leflunomide—Feeling abnormal—Methotrexate—systemic scleroderma	3.19e-05	0.000247	CcSEcCtD
Leflunomide—Diarrhoea—Prednisone—systemic scleroderma	3.17e-05	0.000246	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.17e-05	0.000246	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF5—systemic scleroderma	3.16e-05	0.00389	CbGpPWpGaD
Leflunomide—Urticaria—Methotrexate—systemic scleroderma	3.08e-05	0.000239	CcSEcCtD
Leflunomide—Dizziness—Prednisone—systemic scleroderma	3.07e-05	0.000238	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—systemic scleroderma	3.06e-05	0.000237	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—systemic scleroderma	3.06e-05	0.000237	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF8—systemic scleroderma	3.02e-05	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD247—systemic scleroderma	3.02e-05	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ITGAM—systemic scleroderma	3.02e-05	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMAD7—systemic scleroderma	2.95e-05	0.00363	CbGpPWpGaD
Leflunomide—Vomiting—Prednisone—systemic scleroderma	2.95e-05	0.000228	CcSEcCtD
Leflunomide—Rash—Prednisone—systemic scleroderma	2.92e-05	0.000227	CcSEcCtD
Leflunomide—Dermatitis—Prednisone—systemic scleroderma	2.92e-05	0.000226	CcSEcCtD
Leflunomide—Headache—Prednisone—systemic scleroderma	2.91e-05	0.000225	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	2.86e-05	0.00352	CbGpPWpGaD
Leflunomide—Hypersensitivity—Methotrexate—systemic scleroderma	2.86e-05	0.000221	CcSEcCtD
Leflunomide—PTK2B—Immune System—TNFAIP3—systemic scleroderma	2.83e-05	0.00348	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BLK—systemic scleroderma	2.8e-05	0.00344	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—systemic scleroderma	2.78e-05	0.000215	CcSEcCtD
Leflunomide—Nausea—Prednisone—systemic scleroderma	2.76e-05	0.000213	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—systemic scleroderma	2.74e-05	0.000212	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—systemic scleroderma	2.65e-05	0.000205	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—systemic scleroderma	2.56e-05	0.000199	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—systemic scleroderma	2.46e-05	0.000191	CcSEcCtD
Leflunomide—Rash—Methotrexate—systemic scleroderma	2.44e-05	0.000189	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—systemic scleroderma	2.44e-05	0.000189	CcSEcCtD
Leflunomide—DHODH—Metabolism—NOS3—systemic scleroderma	2.44e-05	0.003	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	2.44e-05	0.00299	CbGpPWpGaD
Leflunomide—Headache—Methotrexate—systemic scleroderma	2.43e-05	0.000188	CcSEcCtD
Leflunomide—Nausea—Methotrexate—systemic scleroderma	2.3e-05	0.000178	CcSEcCtD
Leflunomide—PTK2B—Immune System—CTLA4—systemic scleroderma	2.29e-05	0.00281	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RHOB—systemic scleroderma	2.28e-05	0.0028	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HSPG2—systemic scleroderma	2.15e-05	0.00264	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CSK—systemic scleroderma	2.08e-05	0.00255	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	1.89e-05	0.00232	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DQB1—systemic scleroderma	1.89e-05	0.00232	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1A—systemic scleroderma	1.79e-05	0.0022	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD40LG—systemic scleroderma	1.78e-05	0.00219	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.36e-05	0.00167	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.2e-05	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EDN1—systemic scleroderma	1.17e-05	0.00143	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.16e-05	0.00142	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.03e-05	0.00126	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—systemic scleroderma	9.35e-06	0.00115	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CTGF—systemic scleroderma	9.07e-06	0.00111	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.79e-06	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—systemic scleroderma	7.97e-06	0.000979	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—systemic scleroderma	7.1e-06	0.000872	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSPG2—systemic scleroderma	6.05e-06	0.000743	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—systemic scleroderma	5.7e-06	0.0007	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSPG2—systemic scleroderma	5.17e-06	0.000635	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—systemic scleroderma	4.7e-06	0.000577	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CTGF—systemic scleroderma	4.58e-06	0.000563	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—systemic scleroderma	3.95e-06	0.000485	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CTGF—systemic scleroderma	3.92e-06	0.000481	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.99e-06	0.000245	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—systemic scleroderma	1.7e-06	0.000209	CbGpPWpGaD
